Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) EBT Margin (2022 - 2025)

Historic EBT Margin for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to 60.53%.

  • Phathom Pharmaceuticals' EBT Margin rose 4627600.0% to 60.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 186.44%, marking a year-over-year increase of 11054300.0%. This contributed to the annual value of 605.08% for FY2024, which is 289263000.0% up from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported EBT Margin of 60.53% as of Q3 2025, which was up 4627600.0% from 191.52% recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' EBT Margin registered a high of 1473.65% during Q1 2022, and its lowest value of 11665.1% during Q4 2023.
  • Over the past 4 years, Phathom Pharmaceuticals' median EBT Margin value was 221.33% (recorded in 2025), while the average stood at 1258.89%.
  • In the last 5 years, Phathom Pharmaceuticals' EBT Margin crashed by -122374500bps in 2023 and then surged by 114139600bps in 2024.
  • Over the past 4 years, Phathom Pharmaceuticals' EBT Margin (Quarter) stood at 572.35% in 2022, then crashed by -2138bps to 11665.1% in 2023, then skyrocketed by 98bps to 251.15% in 2024, then soared by 76bps to 60.53% in 2025.
  • Its EBT Margin was 60.53% in Q3 2025, compared to 191.52% in Q2 2025 and 330.64% in Q1 2025.